BioSpace News Archive

Sorrento Therapeutics, Inc. announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader Panel Discussion that will focus on the great unmet need in non-small cell lung cancer and the potential of abivertinib, a novel, third-generation, EGFR/BTK inhibitor.

Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present one-year safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD).

A new study published in The New England Journal of Medicine finds that for adults with Type 1 diabetes and sub-optimal glycemic control, Abbott’s FreeStyle Libre® 2 glucose monitoring system provided significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose (SMBG), which were sustained for the study duration of 24 weeks.

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced the company will be presenting five poster presentations including the MARINA™ study design for myotonic dystrophy type 1 and preclinical and real-world data from the facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD) programs.

Amgen announced the opening of a new research and development site in San Francisco’s Oyster Point, continuing the company’s nearly two-decade presence in the region.

CHS USA Inc., a company of Canadian Hospital Specialties Limited, completed the acquisition of Medical Imaging Solutions International., effective September 16th, 2022.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has successfully imaged its first participant in the US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with PSMA-negative prostate cancer.

Addiction Cure Therapeutic Sciences Inc. an International Rx Solution Company targeting drug and alcohol addiction cures and treatments, announced results from their epigenetic testing.

Heart Test Laboratories, Inc. today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, has been invited to present at the 2022 MicroCap Rodeo Windy City Roundup Conference, which is being held on October 12 - 13, 2022 in Chicago, Illinois.

Milestone Scientific Inc. today announced that Arjan Haverhals, Chief Executive Officer of Milestone Scientific, has been invited to present at the 2022 MicroCap Rodeo Windy City Roundup Conference, which is being held on October 12 - 13, 2022 in Chicago, Illinois.